[The present status of, and problems with the development of FLT3 kinase inhibitors].
Kiyoi
Hitoshi
H
D000328:Adult; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D018833:Chaperonins / Q000037:antagonists & inhibitors; D002648:Child; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics*
C498362:CDC37 protein, human; D018797:Cell Cycle Proteins; D010879:Piperazines; D011799:Quinazolines; C464670:tandutinib; C497970:FLT3 protein, human; D011505:Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; D011493:Protein Kinase C; D018833:Chaperonins; D019311:Staurosporine; C059539:midostaurin